Contact this trialFirst, we need to learn more about you.
PARP Inhibitor
Cediranib + Olaparib for Advanced Prostate Cancer
Recruiting1 awardPhase 2
Boston, Massachusetts
This trial looks at how well olaparib, with or without cediranib, works to treat patients with metastatic prostate cancer. Olaparib is a PARP inhibitor, which means it prevents PARP proteins from repairing DNA mutations. This may stop tumor cells from growing. Cediranib is an enzyme inhibitor that may also stop tumor cell growth.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.